FDA Solicits Comments on Pediatric Codeine Use, Role of Genetic Testing

The FDA is asking for physician and other stakeholder input on the potential use of cytochrome P450 2D6 (CYP2D6) genotyping in children under the age of 12 years prior to potentially treating them with analgesic products that include codeine.